LEADING PRODUCT CANDIDATE
Bluejay Diagnostics is pleased to present Symphony, a near-patient biomarker detection platform. Symphony aims to help improve healthcare outcomes by providing quantitative clinical chemistry results vital for triage and acute care..
Symphony is an innovative implementation of the traditionally reliable ELISA methodology combined with modern advances in nanotechnology. The unique design features a combination of microfluidics and interrupted fluid dynamics to offer fast, simple, safe, and highly sensitive biomarker detection.
*Not FDA cleared. For research use only
PRODUCTS IN DEVELOPMENT
Symphony is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated in the cartridge. Symphony utilizes a ‘sample-to-result’ format, which means that once a specimen is taken from the patient, it is placed in the cartridge and then the cartridge is placed inside the analyzer where the test is run without further technician intervention or additional reagent. This reduces test complexity and eliminates the need for highly trained and expensive laboratory technicians to run the tests. Our platform is designed to enable simple, rapid, and cost-effective analysis from a single clinical sample, which will allow LTACs, hospitals and clinics that traditionally could not afford more expensive or complex diagnostic testing platforms to modernize their laboratory testing and provide better patient testing at an affordable cost in time sensitive, life threatening situations.
Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay’s clinical development programs and provide strategic medical and scientific leadership to the Company.
Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results
ACTON, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost…
Appointment of Fred S. Zeidman to the Board of Directors of Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc. (the "Company"), announced today that Mr. Fred S. Zeidman has been appointed to the Boards of Directors...